Our proprietary gp96 platform activates the human immune system to combat infectious diseases. Collaborators of Heat Biologics’ have laid a good foundation on engineering different pathogenic antigens into our platform. Previous preclinical studies using gp96 platform includes SIV/HIV, malaria and zika. The company initiated a COVID-19 vaccine collaboration with the University of Miami in March 2020.
Heat Biologics’ COVID-19 vaccine program focuses on engineering multiple protein regions of the virus into our gp96 platform. Such design has the potential of generating long-term immune responses and may confer immunity to different coronaviruses.
About Coronavirus
COVID-19 is caused by a new kind of coronavirus (SARS-CoV-2) that first emerged in December 2019. Coronavirus is an RNA-enveloped virus (70-120 nm in diameter) surrounded by characteristics spike-shaped proteins to mediate the attachment and entry into the cell.
Program | Mechanism of Action (Modality) |
Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|---|---|
COVID-19 / Biodefense Initiative |
gp96+Pathogen-Derived Antigens (Cell Therapy) |
Infectious Disease |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|